• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

OncoCyte (OCX) to Acquire Insight Genetics

Share:

February 10, 2020

Oncocyte Corporation (NYSE: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it has closed its previously announced merger agreement with Insight Genetics (IG). The acquisition expands the decision points addressed by Oncocyte’s portfolio of tests with the addition of a potentially transformative immuno-oncology diagnostic test and will also add diverse technology and pharma service offerings including targeted therapeutic panels and a pharma trial lab compliant with 21 C.F.R Parts 820 and 11.

“The Insight Genetics’ IM Score test was an ideal addition to the Oncocyte portfolio, and while our current focus is on lung cancer, this acquisition significantly expands our suite of proprietary tests to manage key decision points potentially across multiple stages and types of cancers,” said Ron Andrews, CEO of Oncocyte. “With immunotherapies currently approved for thirteen solid tumors and additional clinical trials in progress to advance these treatments to earlier stages of cancer, there is a growing need for accurate immunotherapy response prediction tests. Data presented at SITC in November show our new IM Score test outperforms two currently marketed tests for immunotherapy selection suggesting this may be a transformative test to identify immunotherapy responders. This acquisition is an important step in the evolution of Oncocyte as it not only expands our impact to a broader patient population but also provides us access to a CLIA certified lab with the certifications required to submit data to regulatory agencies around the world. Having the ability to truly partner with pharma companies and assist in their global regulatory approvals will help us grow significant new opportunities for pharma services in the expanding immunotherapy and companion diagnostic markets. We are proud of our exceptional progress and look forward to continued growth as we establish Oncocyte as leaders in lung cancer diagnostics and beyond.”

At closing, Oncocyte delivered $6.4 million in cash, which was net of a $0.6 million cash holdback, plus 1.9 million shares of Oncocyte common stock valued at $5 million.

This general description is qualified in its entirety by the terms of the Agreement and Plan of Merger that will be filed as an exhibit to Oncocyte’s Form 8-K on or about February 5, 2020.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Source: StreetInsider

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Consumers Willing to Utilize Medical Wearables to Avoid Physician VisitsConsumers Willing to Utilize Medical Wearables to Avoid Physician Visits
  • NextGen Acquires OTTO Health to Expand Telemedicine CapabilitiesNextGen Acquires OTTO Health to Expand Telemedicine Capabilities
  • Green Hygienics Holdings Inc. Acquires the Canna Brands IP Assets PortfolioGreen Hygienics Holdings Inc. Acquires the Canna Brands IP Assets Portfolio
  • Cytocom Inc. Announces Completed Merger with Cleveland BioLabsCytocom Inc. Announces Completed Merger with Cleveland BioLabs
  • Centene : Announces Purchase Of Expanded Stake In Ribera SaludCentene : Announces Purchase Of Expanded Stake In Ribera Salud
  • Aspen Surgical Acquires BlueMed Medical SuppliesAspen Surgical Acquires BlueMed Medical Supplies
  • Calibrate Wants to Fix America’s Metabolic Health with $5 MillionCalibrate Wants to Fix America’s Metabolic Health with $5 Million
  • ConcertAI Scores $150M, Valuation Skyrockets to Nearly $2BConcertAI Scores $150M, Valuation Skyrockets to Nearly $2B

Trending This Week

  • In the wake of Dobbs, women’s health is ‘Ripe for investment’
  • Market Skeptical Following Sen. Warren’s Antitrust Allegations
  • New tools and acquisitions from OptumRx, ScionHealth.
  • Rogers, Shaw tick lower amid a report that Industry Minister in no hurry to Ok deal
  • ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, furthering its Ambition to Become the Global Leader in Regenerative Therapies
  • LGM Pharma Acquires Pharmaceutical Development and Manufacturing Unit of Nexgen Pharma

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications